SURSECUR™ NPA 2026 — 6:8 MEDICAL SOLUTIONS

IS IT REALLY AN EVOLUTION OF THE CONVENTIONAL NASOPHARYNGEAL AIRWAY?

Scientific, medical, technical, tactical, engineering, Human Factors, and institutional procurement analysis

TCCC • TECC • EMS • Tactical Medicine • Austere Medicine • Airway Management • Human Factors • Medical Device Engineering

Scientific update: September 2026

By DrRamonReyesMD
EMS Solutions International

---

ABSTRACT

The nasopharyngeal airway —Nasopharyngeal Airway, NPA— is probably one of the simplest devices in emergency medicine.

Precisely for that reason, it is interesting that, after decades of using essentially the same concept —a flexible curved tube with a distal opening and a proximal flange— a product has appeared that attempts to correct some of its most common mechanical failure modes without turning a simple intervention into a complex one.

The SURSECUR™ Nasopharyngeal Airway, developed by 6:8 Medical Solutions, incorporates three main modifications compared with a conventional NPA:

1. A proximal stabilization system intended to limit rotation and migration.

2. Fenestrations near the distal tip that provide additional potential pathways for airflow.

3. Medical-grade silicone construction with high elasticity, according to the manufacturer, intended to reduce permanent deformation during storage and use.

The currently marketed product is presented in a 28 Fr / 7.0 mm configuration, is intended for single-patient use, is latex-free, and has a stated five-year shelf life. The current direct U.S. price published by 6:8 Medical Solutions is USD 5.95 per unit. (68medical.com)

From an engineering perspective, the concept is coherent.

From an economic perspective, its incremental cost compared with some conventional 28 Fr NPAs is small.

From an operational perspective, the stabilization system may be particularly attractive during extrication, evacuation, stretcher movement, ground or aeromedical transport, and care in austere environments.

However, a rigorous scientific audit requires separating:

MECHANICAL PLAUSIBILITY

from

BENCH DEMONSTRATION

from

PROVEN CLINICAL SUPERIORITY.

As of September 2026, I have not identified a peer-reviewed comparative clinical trial specifically evaluating SURSECUR™ that demonstrates a lower rate of displacement, obstruction, complications, or clinical failure compared with a conventional NPA.

Therefore, SURSECUR should currently be regarded as a clinically plausible and operationally interesting engineering innovation that still requires independent comparative validation.

That is not an exceptional weakness.

It is exactly the level of evidence that should be acknowledged when properly evaluating an emerging medical technology.

---

1. WHAT IS SURSECUR™?

SURSECUR™ is a nasopharyngeal airway developed by the U.S. company 6:8 Medical Solutions for prehospital medicine, Tactical EMS, TCCC/TECC, disaster response, and austere medicine.

The company states the following specifications:

28 Fr / 7.0 mm

Medical-grade silicone

Latex-free

Single-patient use

5-year shelf life

TAA compliant

and use of its SurGrip™ opening system. (68medical.com)

The most obvious distinguishing feature is a proximal structure referred to by the company as the:

SurSecur™ Anti-Rotation Clip.

Its stated purpose is to:

reduce rotation;

make proximal migration more difficult;

maintain orientation;

and externally provide a reference for the position of the distal bevel. (68medical.com)

Several fenestrations are also incorporated near the distal tip.

---

2. THE INTELLECTUAL PROPERTY IS VERIFIABLE

Public documentation allows the originator of the concept to be identified.

The U.S. application:

US20260166249A1

NASOPHARYNGEAL AIRWAY DEVICE

was published on June 18, 2026.

It identifies:

Inventor: Uriah Shane Popp

Applicant: 6:8 Medical Solutions LLC

Application number: 19/417,820

Filed: December 12, 2025

and claims priority from a provisional application filed on December 12, 2024. (patents.justia.com)

The application specifically describes:

a tubular body;

a primary lumen;

a beveled distal end;

one or multiple fenestrations near the distal end;

and a proximal clip intended to resist axial rotation and make inadvertent withdrawal more difficult. (patents.justia.com)

This matters because it allows us to verify that the concept is not merely a marketing construction created after the product was launched.

There is a formally described technical architecture behind it.

LEGAL PRECISION

However, the terminology must be used correctly.

The record I was able to verify is a:

U.S. PATENT APPLICATION PUBLICATION.

Therefore, I would not use the existence of US20260166249A1 as proof that a U.S. utility patent has already been granted specifically for SURSECUR.

The company publicly uses expressions such as “patented.”

For institutional documentation, the exact numbers of any granted patents applicable to the product should be requested.

---

3. WHO IS URIAH POPP?

6:8 Medical Solutions officially identifies Uriah Popp as:

Founder / CEO

U.S. Army Special Operations and Special Mission Unit Medic

Inventor / Product Developer. (68medical.com)

This is relevant, although it must not be confused with scientific evidence.

A device does not work better because its inventor has a military background.

However, there is a meaningful difference between:

a generic product commercialized by a company with no clear identification of its origin;

and a device whose designer is publicly identified, explains the problem he is attempting to solve, presents prototypes, and participates directly in technical discussion.

Popp clearly falls into the second category.

---

4. THE PROBLEM IT IS TRYING TO SOLVE

A conventional NPA performs a relatively simple function.

It introduces a lumen from the nose into the nasopharynx to help prevent upper-airway soft tissues from completely compromising airflow.

But correctly placing an NPA does not mean that it will remain exactly the same throughout an evacuation.

The patient may:

be moved;

be extricated;

be transferred between stretchers;

receive assisted ventilation;

travel over uneven terrain;

be transported by aircraft;

have blood or secretions;

or undergo repeated handling.

Under those circumstances, the following may occur:

migration

rotation

proximal displacement

poor distal orientation

deformation

partial obstruction.

The SURSECUR patent application itself describes these phenomena as problems associated with conventional NPAs that the design attempts to address. (patents.justia.com)

---

5. ANTI-ROTATION: POSSIBLY ITS MAIN INNOVATION

The proximal clip is the most mechanically interesting element.

Its function is not merely to prevent the airway from disappearing into the nostril.

It is intended to create mechanical interaction with the external nasal anatomy.

That creates resistance to:

axial rotation

and

accidental backing-out or withdrawal.

The patent application specifically describes both functions. (patents.justia.com)

From a Human Factors perspective, this makes sense.

The clinician no longer depends solely on:

friction between the tube and mucosa;

the proximal flange;

or improvised fixation with tape.

SURSECUR integrates that function into the device itself.

---

6. BEVEL ORIENTATION

There is another interesting consequence.

If the clip maintains a fixed relationship with the body of the NPA, it can act as an external reference for distal orientation.

In other words:

the provider can approximately infer where the bevel is pointing without directly visualizing the tip inside the nasopharynx.

The manufacturer presents this feature as a way to reduce uncertainty regarding orientation during use and transport. (68medical.com)

This may be particularly useful in:

night operations;

tactical environments;

gloved use;

poor lighting;

or evacuation.

---

7. DISTAL FENESTRATIONS: AIRFLOW REDUNDANCY

The second major design change is the fenestrations.

A conventional NPA depends primarily on patency of the lumen and the distal opening.

If the tip rests against mucosa or becomes partially obstructed by:

tissue;

secretions;

blood;

or poor positioning,

airflow resistance may increase.

SURSECUR incorporates side openings near the distal end.

The intellectual property specifically describes these fenestrations as:

auxiliary airflow pathways. (patents.justia.com)

The concept can be summarized as:

ONE PRIMARY LUMEN

but

MULTIPLE POTENTIAL DISTAL COMMUNICATION POINTS.

From an engineering standpoint, redundancy is reasonable.

But there is a critical scientific distinction.

WHAT WE KNOW

The fenestrations exist and theoretically provide additional pathways for airflow.

WHAT STILL NEEDS TO BE DEMONSTRATED

How much airflow they preserve when the main distal opening is:

partially occluded;

completely occluded;

covered by mucosa;

exposed to blood;

exposed to viscous secretions.

That analysis should be performed with standardized resistance and flow testing.

---

8. MEDICAL-GRADE SILICONE

The official page states that SURSECUR is manufactured from medical-grade silicone and claims that it provides high elasticity and resistance to permanent deformation seen in some PVC devices. (68medical.com)

This has operational relevance.

An NPA may remain:

for months;

or years,

compressed inside an:

IFAK;

aid bag;

vehicle kit;

backpack;

tactical pouch.

When it is finally needed, it should recover its geometry.

A deformed airway could affect:

insertion;

direction;

distal position;

and possibly airflow resistance.

PLATINUM SILICONE

The promotional post shown by 6:8 Medical Solutions also uses the term:

PLATINUM SILICONE.

The public product documentation I was able to verify uses the broader and unambiguous term:

medical-grade silicone. (68medical.com)

Therefore, for an institutional tender, I would request:

material-composition certification;

curing type;

biocompatibility documentation;

applicable ISO 10993 data;

and the final technical data sheet.

Not because there is evidence of a problem.

Because a commercial specification and a regulatory specification are not the same thing.

---

9. DOES IT REALLY ELIMINATE THE NEED FOR TAPE?

The product advertising emphasizes that the stabilization mechanism is integrated directly into the NPA.

The official page specifically notes that, unlike devices that rely on tape or secondary fixation, SURSECUR uses an integrated clip. (68medical.com)

The technically correct interpretation would be:

SURSECUR IS DESIGNED TO REDUCE DEPENDENCE ON ADDITIONAL EXTERNAL FIXATION.

I would avoid converting that into:

“it never needs tape under any circumstances.”

Clinical judgment and context still prevail.

But from an operational engineering standpoint, removing a potential step has value.

---

10. FEWER STEPS = FEWER OPPORTUNITIES FOR ERROR

In Human Factors, an important principle is:

every additional action introduces another opportunity for failure.

Finding tape.

Finding the end.

Cutting it.

Getting adhesion on:

sweat;

blood;

water;

mud;

or contaminated skin.

All of that consumes:

time;

attention;

and manual capability.

In an emergency department, that may be trivial.

Inside a moving vehicle, at night, while wearing gloves, it may not be.

That is why integrating stabilization into the device itself has considerable operational logic.

---

11. SURGRIP™ PACKAGING

6:8 Medical Solutions also markets the device using its SurGrip™ easy-open packaging system. (68medical.com)

This may seem like a minor detail.

It is not necessarily minor.

In emergency equipment, the following matter:

how quickly it can be identified;

how quickly it can be opened;

whether it can be handled with gloves;

and how many movements are required before it can be used.

Reducing cognitive load is a legitimate component of medical-device design.

---

12. THE MAJOR DOCTRINAL CORRECTION: TCCC 2026

This point requires precision.

For years, many TCCC courses essentially taught:

unconscious casualty → NPA → recovery position.

The doctrine evolved.

The airway change approved in 2024 significantly simplified the algorithm and de-emphasized routine use of airway devices.

The scientific article documenting TCCC Change 24-1 notes that previous recommendations were removed and that the NPA became particularly relevant in the context of:

impaired ventilation + uncorrectable hypoxia + BVM, using a properly sized NPA. (pubmed.ncbi.nlm.nih.gov)

The current TCCC Guidelines, updated on May 1, 2026, retain that logic.

In the Respirations/Breathing section, they indicate that if the casualty has impaired ventilation and uncorrectable hypoxia, with saturation falling below 90% —or 92% in moderate/severe TBI— a properly sized nasopharyngeal airway may be considered while ventilating with a 1000 mL BVM. (books.allogy.com)

The official TCCC 2026 update is documented by Deaton, Montgomery, and Butler and published in the Journal of Special Operations Medicine. (pubmed.ncbi.nlm.nih.gov)

---

13. WHY THIS IS ESPECIALLY IMPORTANT FOR SURSECUR

SURSECUR attempts to solve:

rotation;

migration;

orientation;

distal redundancy.

But there is another problem the current design does not eliminate:

SIZING.

The Joint Trauma System CPG:

AIRWAY MANAGEMENT IN TRAUMA

JANUARY 28, 2026

continues to recognize the NPA as an airway adjunct, but specifically lists among its disadvantages:

nose bleeding

and

sizing challenges. (jts.health.mil)

This is consistent with analysis previously published by EMS Solutions International, which noted that the TCCC review identified inconsistencies in length and size among NPAs stored in IFAKs and aid bags, with the possibility that an excessively long airway could create problems and with a resulting reduction in the doctrinal prominence of the NPA. (emssolutionsint.blogspot.com)

This is essential.

A well-secured but poorly sized NPA remains a poorly sized NPA.

---

14. 28 Fr DOES NOT FIT EVERYONE

At present, I have been able to publicly verify SURSECUR in:

28 Fr / 7.0 mm. (68medical.com)

A standardized adult size may be perfectly reasonable for:

IFAKs;

adult military personnel;

law enforcement;

Tactical EMS;

rescue teams.

But it does not replace a full range of sizes when treating:

children;

adolescents;

small adults;

or patients with extreme anatomical variation.

Therefore:

SURSECUR MAY BE A VERY INTERESTING STANDARD ADULT NPA.

But at present it cannot be considered:

A UNIVERSAL SIZING SOLUTION.

---

15. A METROLOGICAL DETAIL THAT SHOULD BE CLARIFIED

The product is marketed as:

28 Fr / 7.0 mm.

However:

1 French = approximately 0.33 mm of external diameter.

Therefore:

28 Fr ≈ 9.3 mm external diameter.

That means the:

7.0 mm

value cannot simply be the metric conversion of 28 Fr.

It probably represents another nominal dimension, possibly internal diameter, but the public page does not identify it clearly enough.

For institutional procurement, I would request:

ID — internal diameter

OD — external diameter

usable length

total length.

That should not remain ambiguous.

---

16. SAFETY: IT IS STILL AN NPA

SURSECUR modifies the device.

It does not modify human anatomy.

An NPA can still cause:

epistaxis;

mucosal trauma;

turbinate injury;

malposition;

obstruction;

or complications associated with traumatic insertion.

The JTS 2026 CPG specifically identifies the risk of nasal bleeding and sizing problems. (jts.health.mil)

It also states that an NPA should not be used when basilar skull fracture is suspected. (jts.health.mil)

The device should still be considered:

AN AIRWAY ADJUNCT.

Not a definitive airway.

---

17. SURSECUR IS NOT “RECOMMENDED BY CoTCCC” AS A BRAND

This point should be absolutely clear.

TCCC recommendations refer to a:

properly sized nasopharyngeal airway.

I have not found a CoTCCC recommendation specifically endorsing:

SURSECUR™

or

6:8 Medical Solutions

as the preferred NPA brand.

Therefore, a scientifically rigorous publication should not state:

“CoTCCC recommends SURSECUR.”

The correct statement is:

SURSECUR BELONGS TO THE NPA DEVICE CLASS THAT MAY BE USED WHEN CLINICALLY INDICATED, BUT TCCC DOCTRINE DOES NOT CONSTITUTE A BRAND ENDORSEMENT.

---

18. EMS SOLUTIONS INTERNATIONAL AND THE EVOLUTION OF TCCC AIRWAY MANAGEMENT

This analysis is consistent with the doctrinal evolution that EMS Solutions International has been documenting.

In its review of the TCCC Guidelines 2026, EMS Solutions International highlights the progressive simplification of airway management and the increased emphasis on:

positioning;

suction;

effective ventilation;

reassessment;

SpO2;

EtCO2;

and appropriate selection of interventions,

rather than converting tactical airway management into an automatic sequence of devices. (emssolutionsint.blogspot.com)

EMS Solutions International has also specifically analyzed the TCCC updates that moved away from presenting the NPA as an automatic intervention for every unconscious casualty and highlighted the problem of sizing. (emssolutionsint.blogspot.com)

This perspective is especially relevant here:

A BETTER DEVICE DOES NOT JUSTIFY AN INCORRECT INDICATION.

First:

the right patient.

Then:

the right device.

Finally:

the right technique and reassessment.

---

19. PRICE IN THE UNITED STATES — SEPTEMBER 2026

The current direct price published by 6:8 Medical Solutions for SURSECUR is:

USD 5.95 / UNIT. (68medical.com)

The price is especially interesting because it is very close to that of conventional NPAs.

At MED-TAC, as of September 2026, the following references are listed:

VETRUN Pre-Lubricated NPA 28 Fr — USD 4.99

MARCH Pre-Lubricated NPA 28 Fr — USD 5.25

SURSECUR 28 Fr — USD 5.95. (tactical-medicine.com)

Therefore:

SURSECUR VS VETRUN

Difference:

USD 0.96

SURSECUR VS MARCH

Difference:

USD 0.70

---

20. WHAT DOES THAT MEAN IN A REAL PROCUREMENT?

Using the published retail prices and excluding volume discounts, shipping, and taxes:

100 SURSECUR UNITS

USD 595

Approximate additional cost compared with 100 VETRUN units:

USD 96

Approximate additional cost compared with 100 MARCH units:

USD 70

500 SURSECUR UNITS

USD 2,975

Difference compared with VETRUN:

approximately USD 480

Difference compared with MARCH:

approximately USD 350

1,000 SURSECUR UNITS

USD 5,950

Difference compared with VETRUN:

approximately USD 960

Difference compared with MARCH:

approximately USD 700.

This is particularly relevant.

We are not evaluating an innovation that multiplies the cost of the traditional device by ten.

We are evaluating a difference of roughly less than one dollar per unit compared with several comparable retail alternatives.

---

21. SO WHY CONSIDER BUYING SURSECUR?

Not because it has a tactical appearance.

Not because its founder comes from Special Operations.

Not because it appears on Instagram.

Not because it has a patent application.

And not because a company says its product is better.

There are stronger technical arguments.

1. INTEGRATED SECUREMENT

It may reduce the possibility of displacement during movement.

2. ROTATION CONTROL

It directly addresses a real mechanical failure mode.

3. EXTERNAL ORIENTATION REFERENCE

The clip may provide information about bevel orientation.

4. DISTAL REDUNDANCY

The fenestrations add additional potential airflow pathways.

5. MEDICAL-GRADE SILICONE

It may provide improved elastic recovery compared with materials more susceptible to compression set.

6. REDUCED DEPENDENCE ON TAPE

It simplifies logistics and removes one step.

7. PACKAGING DESIGNED FOR USE UNDER STRESS

Relevant to EMS and Tactical Medicine.

8. COST

The price increase compared with conventional alternatives is small.

---

22. ITS MAIN COMPETITOR IS NOT ANOTHER BRAND

SURSECUR’s main conceptual competitor is:

THE FIVE-DOLLAR CONVENTIONAL NPA THAT ALREADY WORKS REASONABLY WELL.

Therefore, the question is not:

“Does SURSECUR work?”

It probably works as an NPA.

The scientifically relevant question is:

DO ITS DESIGN MODIFICATIONS PROVIDE ENOUGH ADVANTAGE TO JUSTIFY REPLACING A CONVENTIONAL NPA?

To answer that definitively, we need comparative data.

---

23. WHAT TESTING SHOULD WE REQUIRE?

A serious study should compare SURSECUR with several conventional NPAs under standardized conditions.

AXIAL RETENTION

Force required to produce:

5 mm withdrawal;

10 mm withdrawal;

complete extraction.

ROTATION

Torque required to produce:

15 degrees;

45 degrees;

90 degrees.

AIRFLOW

Resistance to flow with:

free distal tip;

25% occlusion;

50% occlusion;

75% occlusion;

100% distal occlusion.

CONTAMINATION

Repeat testing using:

simulated blood;

mucin;

artificial secretions.

STORAGE

Evaluate geometry after:

3 months;

6 months;

12 months

under compression and elevated temperature.

HUMAN FACTORS

Measure:

opening time;

placement time;

errors;

orientation;

need for readjustment;

use with gloves;

use in darkness.

---

24. AND THEN WE NEED CLINICAL DATA

Subsequent studies should investigate:

epistaxis;

mucosal injury;

tolerance;

displacement during transport;

need for repositioning;

effective ventilation;

adverse events.

Only then could we scientifically claim:

CLINICAL SUPERIORITY.

Until then, we can speak of:

POTENTIAL DESIGN SUPERIORITY OR DESIGN ADVANTAGE.

That distinction matters.

---

25. THE 6:8 MEDICAL PHILOSOPHY

There is another interesting point.

SURSECUR is not an isolated product in the company’s portfolio.

6:8 Medical Solutions also develops:

directed-pressure systems;

hemorrhage-control dressings;

hypothermia systems;

ProCric™;

and other prehospital devices. (68medical.com)

EMS Solutions International has already analyzed some of them.

The article:

6:8 MEDICAL TOURNIQUET — A NEW GENERATION OF HEMORRHAGE CONTROL

analyzed the focal-pressure philosophy and the Popp Point Pressure concept from tactical and physiological perspectives. (emssolutionsint.blogspot.com)

EMS Solutions International also performed a specific review of the:

ProCric™ Emergency Cricothyrotomy Kit

including its architecture, documentation, components, and limitations. (emssolutionsint.blogspot.com)

A common pattern becomes visible:

6:8 attempts to identify small failure points in established devices and redesign around them.

---

26. URIAH POPP + SAM SLISHMAN: THE COLLABORATION EXISTS

I repeated the audit here as well.

Samuel Slishman, MD, is an emergency physician and medical-device inventor.

His own professional website identifies him as:

Emergency Physician · Inventor

and documents, among other technologies, the Slishman Traction Splint, Slishman Pressure Wrap, and various educational and simulation platforms. (slishman.com)

During September 2026, there are verifiable publications in which:

SAM SLISHMAN AND URIAH POPP APPEAR TOGETHER PERFORMING EXPERIMENTS.

These are not merely social photographs.

---

27. EXPERIMENT 1 — INITIAL CINCH

On September 12, 2026, they jointly published a sequence focused on:

INITIAL CINCH.

The objective was to study how initial slack removal in a tourniquet changes the system’s later ability to generate pressure.

The publication explicitly identifies:

Sam Slishman

and

Uriah Popp

as the two inventors participating in the demonstration. (imginn.com)

The question is mechanically relevant:

a windlass does not begin effectively compressing tissue if it first has to consume a significant amount of slack.

---

28. EXPERIMENT 2 — PRESSURE DROP

In the second part, they examined how system pressure changes as simulated limb volume decreases.

The publication uses the concept:

PRESSURE DROP OF THE THIRD SPACE.

The objective was to evaluate how progressive loss of volume may alter pressure applied by the device and how much mechanical reserve proper initial tension leaves for later compensation. (imginn.com)

This connects with a fundamental clinical concept:

NO TACTICAL INTERVENTION IS “FIRE AND FORGET.”

Reassessment is essential.

---

29. DIRECTED-PRESSURE EXPERIMENTS

Another series uses models with independent compartments and hydrostatic measurement to study:

where pressure is actually being generated.

Not merely:

“how much total pressure the device produces.”

The methodology shown uses manometry and fluid-filled chambers to observe differences between:

localized pressure;

and pressure distributed around the limb. (imginn.com)

This is conceptually relevant to the entire Popp Point Pressure philosophy.

---

30. EMERGENCY BANDAGE VS HEMGUARD

In one of those comparative demonstrations, the reported values were approximately:

40 mmHg of localized pressure beneath the bar of the Emergency/Israeli-style bandage

versus approximately:

62 mmHg with HemGuard

in that particular experimental model. (imginn.com)

The publication itself attributes the difference to the geometry of HemGuard’s pressure element and the concentration of force over the target.

It is a visually interesting result.

But it must be interpreted correctly.

---

31. THAT IS NOT YET A CLINICAL TRIAL

The Popp-Slishman experiments have value as:

bench testing

proof of concept

mechanistic demonstration

education

hypothesis generation.

They are not equivalent to:

a randomized controlled trial;

a multicenter clinical study;

or evidence of mortality reduction.

To convert those results into clinical science, we would need:

a defined protocol;

calibrated equipment;

repetition;

adequate sample size;

variability assessment;

controls;

statistical analysis;

and independent validation.

That does not diminish the value of the experiments.

It simply places them at the correct level of evidence.

---

32. IS SAM SLISHMAN A “STRATEGIC PARTNER” OF 6:8?

There is clearly:

public collaboration;

joint experimentation;

intellectual exchange;

discussion of devices;

and a friendly professional relationship.

Slishman has publicly referred to Popp as a friend and has shown technologies developed by him in his own demonstrations. (linkedin.com)

But I have not found sufficient corporate documentation to state that:

SAMUEL SLISHMAN IS FORMALLY A CONTRACTUAL “STRATEGIC PARTNER” OF 6:8 MEDICAL SOLUTIONS.

Therefore, scientifically, I would use:

A PUBLICLY VISIBLE TECHNICAL AND INTELLECTUAL COLLABORATOR OF URIAH POPP.

That is documented.

And it is sufficiently significant.

---

33. WHAT INTERESTS ME ABOUT THAT RELATIONSHIP

It is not simply that two inventors appear together in videos.

It is that they publicly show:

questions;

models;

prototypes;

variables;

unexpected results;

and discussion.

Sam Slishman even maintains an educational approach explicitly centered on:

QUESTIONS & EXPERIMENTS

regarding hemorrhage control and device mechanics. (slishman.com)

That approach:

ask → measure → modify → test again

is exactly the culture that should surround prehospital medical-device development.

---

34. REGULATION: PRECISION IS ESSENTIAL HERE

The official SURSECUR page states:

CE marked / FDA listed. (68medical.com)

I was able to independently verify that:

6:8 MEDICAL SOLUTIONS

appears as an active establishment in the FDA database during 2026 with:

Registration Number 3034286095. (accessdata.fda.gov)

I was also able to verify a specific FDA listing corresponding to a compression device marketed under 6:8 Medical Solutions. (accessdata.fda.gov)

However, in the public search performed, I was not able to locate a specific device-listing record that unequivocally identified SURSECUR by trade name.

This does not prove that no such listing exists.

It simply means that:

“FDA LISTED” FOR SURSECUR SHOULD CURRENTLY BE ATTRIBUTED TO THE MANUFACTURER UNTIL THE SPECIFIC LISTING IS AVAILABLE.

And remember:

FDA registered

or

FDA listed

DOES NOT automatically mean:

FDA approved.

These are different regulatory concepts.

---

35. TWO DOCUMENTATION INCONSISTENCIES THAT 6:8 SHOULD CLARIFY

The audit identified two details that matter for procurement.

FIRST: NSN

The official SURSECUR page shows:

NSN 6515-01-737-1154. (68medical.com)

But the official:

ProCric™

page shows exactly the same:

NSN 6515-01-737-1154. (68medical.com)

They are different products.

Therefore, before entering that number into:

a tender;

military logistics system;

requisition;

or institutional catalog,

it should be confirmed directly with 6:8 Medical Solutions or through the official NSN system.

This is probably a website-content error.

But it should be corrected.

---

36. SECOND: WEIGHT AND DIMENSIONS

The public documentation is not completely consistent here either.

One SURSECUR page lists approximately:

9 × 3 × 0.5 inches / 3 oz. (68medical.com)

Another official page gives:

8.5 × 2.75 × 0.5 inches / 2 oz

while its automated additional-information section shows different figures. (68medical.com)

For an individual clinical user, this is irrelevant.

For procurement, master-carton planning, air cargo, or precise IFAK configuration:

it is not.

The current revised technical data sheet should be used, not merely the commercial webpage.

---

37. IS IT PRE-LUBRICATED?

This detail also matters.

Competitors such as:

VETRUN

and

MARCH

are explicitly marketed as:

pre-lubricated. (tactical-medicine.com)

The public SURSECUR documentation I reviewed does not state with equal clarity that the unit is pre-lubricated.

This should be confirmed before configuring an IFAK.

If separate lubricant is required:

it must be included.

An excellent NPA without lubricant available at the point of use is not an operational improvement.

---

38. WHY 6:8 MEDICAL DESERVES ATTENTION

There is no scientific reason to buy a brand solely because the inventor:

“shows his face.”

But there are reasons to view a company positively when:

the designer is identifiable;

the intellectual property is traceable;

failure modes are defined;

the manufacturer provides educational material;

there is open interaction with clinicians;

the devices can be publicly examined and criticized;

and the price remains competitive.

6:8 meets many of those criteria.

---

39. THE PARALLEL WITH PROCRIC™

EMS Solutions International had already identified a similar philosophy in ProCric™.

That device also attempts to address a problem that appears after a technically correct intervention has already been performed:

DEVICE STABILITY DURING MOVEMENT AND VENTILATION. (emssolutionsint.blogspot.com)

SURSECUR does something conceptually similar.

It does not reinvent the NPA.

It attempts to prevent an initially correct NPA from becoming incorrectly positioned.

---

40. THE GENERAL PRINCIPLE: DESIGN AROUND THE FAILURE MODE

A good medical device does not necessarily require sophisticated technology.

Sometimes it simply answers one question:

HOW DOES WHAT WE ALREADY USE ACTUALLY FAIL?

With an NPA:

Does it rotate?

Does it back out?

Does it lose orientation?

Does it deform?

Does it become distally obstructed?

If the answer is yes, the designer can modify exactly those points.

That is:

FAILURE-MODE-DRIVEN DESIGN.

And that is probably the most interesting aspect of SURSECUR.

---

41. WOULD I BUY IT?

For a system involving:

EMS;

Tactical EMS;

TCCC;

protective medicine;

remote teams;

CASEVAC;

aeromedical evacuation;

or adult IFAKs,

I would include it in an:

OPERATIONAL PILOT EVALUATION.

I would not automatically replace thousands of conventional NPAs based solely on marketing.

I would initially purchase a sufficiently large batch for comparative testing.

---

42. WHAT I WOULD PERSONALLY TEST

I would compare SURSECUR directly with a conventional 28 Fr NPA.

I would evaluate:

OPENING TIME

TIME TO PLACEMENT

USE WITH GLOVES

USE IN DARKNESS

MIGRATION DURING TRANSPORT

ROTATION

EXTRACTION FORCE

RECOVERY AFTER COMPRESSION IN AN IFAK

AIRFLOW WITH PARTIALLY OCCLUDED DISTAL TIP

AIRFLOW WITH COMPLETELY OCCLUDED DISTAL TIP

BEHAVIOR WITH SIMULATED BLOOD

BEHAVIOR WITH SECRETIONS

EASE OF BVM VENTILATION

NUMBER OF REPOSITIONINGS REQUIRED.

And I would publish the results.

---

43. WHAT WE SHOULD NOT DO

We should not say:

“it is better because it looks better.”

Nor:

“it is TCCC because it appears in tactical equipment.”

Nor:

“FDA registered means FDA approved.”

Nor:

“it has a patent” when what we have in front of us is only a published patent application.

Nor:

“Sam Slishman is a contractual strategic partner” without documentation confirming it.

Tactical medicine needs innovation.

But it also needs:

RIGOR.

---

44. MY FINAL TECHNICAL ASSESSMENT

SURSECUR represents one of the more rational modifications I have recently seen applied to an extremely simple device.

It does not attempt to add:

electronics;

batteries;

sensors;

Bluetooth;

software;

or unnecessary complexity.

It preserves the basic essence of a conventional NPA.

But it adds:

STABILIZATION

ROTATION CONTROL

ORIENTATION REFERENCE

and

DISTAL REDUNDANCY.

All for approximately:

USD 5.95.

That balance between:

simplicity;

cost;

and potential operational benefit

is probably its strongest commercial argument. (68medical.com)

---

45. WHY WOULD I CONSIDER BUYING THIS BRAND?

Because the incremental cost is small.

Because the engineering modifications address plausible and known problems.

Because the manufacturer publicly identifies the inventor.

Because the intellectual property is traceable.

Because the company allows its development process to be observed.

Because there is dialogue with physicians and external inventors.

Because Uriah Popp and Sam Slishman are publicly performing mechanical and comparative experiments related to prehospital technologies. (imginn.com)

And because 6:8 appears to follow a philosophy that EMS Solutions International has already identified in other company products:

IDENTIFY A REAL FAILURE → SIMPLIFY THE SOLUTION → INTEGRATE IT INTO THE DEVICE. (emssolutionsint.blogspot.com)

But buying this brand responsibly also means requiring:

data;

regulatory documentation;

logistics consistency;

independent validation;

and scientific publication.

---

CONCLUSION

SURSECUR™ DOES NOT REINVENT THE AIRWAY.

It probably does something smarter.

IT ATTEMPTS TO IMPROVE AN NPA WITHOUT CEASING TO BE AN NPA.

The technical concept is sound:

integrated stabilization clip;

resistance to rotation;

external bevel-orientation reference;

distal fenestrations;

medical-grade silicone;

packaging designed for use under stress.

The published patent application demonstrates that there is a formal design behind the concept. (patents.justia.com)

The price of USD 5.95 makes the economic barrier surprisingly low. (68medical.com)

The public collaboration between Uriah Popp and Sam Slishman exists and includes real experiments involving tourniquet mechanics and pressure distribution. (imginn.com)

But rigor also requires us to say:

SURSECUR STILL NEEDS INDEPENDENT COMPARATIVE EVIDENCE DEMONSTRATING CLINICAL SUPERIORITY.

And there is another, even more important lesson.

TCCC 2026 no longer simply teaches:

“unconscious = NPA.”

Contemporary doctrine requires:

select the right patient;

size correctly;

ventilate when necessary;

monitor;

and reassess continuously. (books.allogy.com)

Therefore, the most important conclusion of this review is not:

“BUY SURSECUR BECAUSE IT IS NEW.”

It is:

SURSECUR DESERVES TO BE PURCHASED AND SUBJECTED TO OPERATIONAL EVALUATION BECAUSE, FOR A VERY SMALL INCREMENTAL COST, IT ATTEMPTS TO SOLVE SEVERAL REAL FAILURE MODES OF THE CONVENTIONAL NPA WITHOUT ADDING SIGNIFICANT COMPLEXITY.

If independent testing confirms the mechanical advantage:

THEN WE CAN SPEAK OF A TRUE EVOLUTION OF THE NPA.

Until then:

MEASURE.

COMPARE.

REASSESS.

PUBLISH.

Because serious medical innovation should not ask us to believe.

It should allow us to:

VERIFY.

---

PRIMARY AND TECHNICAL REFERENCES

6:8 Medical Solutions — SURSECUR™ Nasopharyngeal Airway.
Technical specifications, pricing, and product features. (68medical.com)

U.S. Patent Application Publication 20260166249 — Nasopharyngeal Airway Device.
Uriah Shane Popp / 6:8 Medical Solutions LLC. Published June 18, 2026. (patents.justia.com)

Joint Trauma System — Airway Management in Trauma CPG. January 28, 2026.
Includes NPA indications, advantages, and limitations, including epistaxis, sizing challenges, and suspected basilar skull fracture. (jts.health.mil)

Joint Trauma System — Tactical Combat Casualty Care Guidelines. May 1, 2026. (jts.health.mil)

Deaton TG, Montgomery HR, Butler FK. Tactical Combat Casualty Care Guidelines: 1 May 2026 Updates. Journal of Special Operations Medicine. 2026;26(2):89-95. DOI 10.55460/J.Spec.Oper.Med.2026.8VSB-B7D7. (pubmed.ncbi.nlm.nih.gov)

Airway Management in Tactical Combat Casualty Care: TCCC Change 24-1.
Describes the modern revision of airway management and the more selective role of the NPA. (pubmed.ncbi.nlm.nih.gov)

FDA — Establishment Registration & Device Listing — 6:8 Medical Solutions.
Active establishment registration during 2026. (accessdata.fda.gov)

Slishman Solutions — Samuel Slishman, MD. Emergency physician and medical-device inventor. (slishman.com)

Popp / Slishman — Initial Cinch experimental series, September 2026. (imginn.com)

Popp / Slishman — Pressure Drop experimental series, September 2026. (imginn.com)

6:8 Medical Solutions / Slishman — Pressure-bandage differential testing, September 2026. (imginn.com)

---

EMS SOLUTIONS INTERNATIONAL — RELATED REFERENCES

TCCC Guidelines 2026 — Critical Technical, Operational, Doctrinal, and Scientific Review.
EMS Solutions International — By DrRamonReyesMD. (emssolutionsint.blogspot.com)

TCCC Tactical Combat Casualty Care Guidelines — Airway / 2026 Update.
EMS Solutions International. (emssolutionsint.blogspot.com)

The TCCC Update Discussed — Airway Changes, NPA, Sizing, and De-emphasis.
EMS Solutions International. (emssolutionsint.blogspot.com)

Tactical Combat Casualty Care TCCC / TC3 by CoTCCC. Guidelines.
Historical archive and doctrinal updates from EMS Solutions International. (emssolutionsint.blogspot.com)

SPECIAL OPERATIONS MEDICINE & TACTICAL COMBAT CASUALTY CARE 2026.
EMS Solutions International — review of Special Operations Medicine, TCCC, and PCC. (emssolutionsint.blogspot.com)

6:8 MEDICAL TOURNIQUET — A New Generation of Hemorrhage Control.
Analysis of the focal-pressure concept used by 6:8 Medical Solutions, SOMA 2026. (emssolutionsint.blogspot.com)

ProCric™ Cricothyrotomy Kit — Technical Analysis 2026.
EMS Solutions International. (emssolutionsint.blogspot.com)

---

By DrRamonReyesMD
EMS Solutions International

Scientific, medical, tactical, and technological review — September 2026

#SurSecur #68MedicalSolutions #NasopharyngealAirway #NPA #AirwayManagement #TCCC #TECC #TacticalMedicine #EMS #CombatMedicine #PrehospitalMedicine #AustereMedicine #MedicalDevices #HumanFactors #UriahPopp #SamSlishman #SOMA2026 #DrRamonReyesMD